Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Davis, Zinna N. (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S355000, C514S356000, C546S273400, C546S315000, C546S321000
Reexamination Certificate
active
11033221
ABSTRACT:
The present invention is directed in part towards methods of modulating the function of calcium channels with pyridine- or 1,4-dihydropyridine-based compounds. In addition, the invention describes methods of preventing and treating protein kinase-related abnormal conditions in organisms with a compound identified by the invention. Furthermore, the invention pertains to pyridine- or 1,4-dihydropyridine-based compounds and pharmaceutical compositions comprising these compounds.
REFERENCES:
patent: 0 220 653 (1987-05-01), None
patent: 0 493 782 (1992-07-01), None
Straub et al, Bioorganic & Medicinal Chemistry Letters, vol. 7, No. 19, pp. 2519-2522, 1997.
Kendurkar et al, Journal of Chemical and Engineering Data, vol. 19, No. 2, pp. 184-188, 1974.
Akaike, N. et al., Low-voltage-activated calcium current in rat aorta smooth muscle cells in primary culture, J. Physiol. 416:141-160 (1989).
Bean, B. P., Nitrendipine block of cardiac calcium channels: high affinity binding to the inactivated state. Proc. Natl. Acad. Sci. USA 81:6388-6392 (1984).
Bech-Hansen, N. T. et al., Loss-of-function mutations in a calcium channel α1-subunit gene in Xp11.23 cause incomplete X-linked congenital stationary night blindness, Nat. Genet. 19:264-267 (1984).
Bourinet, E. et al., Splicing of alpha-1a subunit gene generates phenotypic variants of P-and Q-type calcium channels, Nat. Neurosci. 2:407-415 (1999).
Carbone, E. and H. D. Lux, A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones, Nature 310:501-502 (1984).
Catterall, W. A., Structure and regulation of voltage-gated Ca2+channels, Annu. Rev. Cell. Dev. Biol. 16:521-555 (2000).
Chaung, R.S. I., et al., Inhibition of T-type voltage gated calcium channel by a new scorpion toxin, Nature Neuroscience, 1:668-674 (1998).
Clozel, J. P., et al., Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker, Journal of Hypertension 15:S17-S25 (1997).
Dubel, S. J. et al., Molecular cloning of the alpha-1 subunit of an omega-conotoxin-sensitive calcium channel, Proc. Natl. Acad. Sci. USA. 89:5058-5062 (1992).
Dunlap, K. et al., Exocytotic Ca2+channels in mammalian central neurons, Trends. Neurosci. 18:89-98 (1995).
Fingl et al. in, The Pharmacological Basis of Therapeutics, Ch. 1 p. 1 (1975).
Goldmann, S. and J. Stoltefuss, 1,4-Dihydropyridines: effects of chirality and conformation on the calcium antagonist and calcium agonist activities, Angewandte Chemie International Edition (English) 30:1559-1578 (1991).
Janis, R. A. and Triggle, D. J., Drugs acting on calcium channels, in Calcium Channels: Their Properties, Functions, Regulation and Clinical Relevance, ch. 13, pp. 195-249 (1990).
Janis, R.A., and D. J. Triggle, New developments in Ca2+channel antagonists, Journal of Medicinal Chemistry, 26:775-785 (1983).
Klugbauer, N. et al., Molecular diversity of the calcium channel alpha2 delta subunit, J. Neurosci. 19:684-691 (1999).
Klugbauer, N. et al., A family of gama-like calcium channel subunits, FEBS Lett. 470:189-197 (2000).
Kumar, P.P. et al., Synthesis and Evaluation of a New Class of Nifedipine Analogs with T-Type Calcium Channel Blocking Activity, Molecular Pharmacology 61-6:649-657 (2002).
Lacinova, L. et al., Regulation of the calcium channel alpha 1G subunit by divalent catiors and organic blockers, Neuropharmacology 39:1254-1266 (2000).
Lacinova, L. et al., Low voltage activated calcium channels: from genes to function, Gen. Physiol. Biophys. 19:121-136, Review (2000).
Loev, B., et al., “Hantzsch-type” dihydropyridine hypotensive agents, Journal of Medicinal Chemistry 17:956-965 (1974).
McRory, J. E. et al., Molecular and functional characterization of a family of rat brain T-type calcium channels, J. Biol. Chem. 275:3999-4011 (2001).
Mehrke, G. et al., The Ca++channel blocker Ro 40-5967 blocks differently T-type and L-type Ca++channels, Journal of Pharmacology and Experimental Therapeutics 271:1483-1488 (1994).
Neelands, T. R. et al., Functional expression of L-, N-, P/Q-, and R-type calcium channels in the human NT2-N cell line, J. Neurophysiol. 84(6):2933-2944 (2000).
Nilius, B. et al., A novel type of cardiac calcium channel in ventricular cells, Nature 316:443-446 (1985).
Nowycky, M. C. et al., Three types of neuronal calcium channel with different calcium agonist sensitivity, Nature 316:440-443 (1985).
Palmer, R. et al., Synthesis and x-ray crystal structure of 1,4-dihydro-2,6-dimethyl-4-(2′-isopropylphenyl)-3,5-pyridine-dicarboxylic acid dimethyl ester: a nifedipine analogue, Bioorganic & Medicinal Chemistry Letters 6-18:2173-2176 (1996).
Peterson, B. Z. and Catterall, W. A., Calcium binding in the pore of the L-type calcium channels modulates high affinity dihydropyridine binding, J. Biol. Chem. 270:18201-18204 (1995).
Peterson, B.Z. et al., Calmodulin is the Ca2+sensor for Ca2+-dependent inactivation of L-type calcium channels, Neuron 22:549-558 (1999).
Pragnell. M. et al., Calcium channel beta-subunit binds to a conserved motif in the I-II cytoplasmic linker of the alpha 1-subunit, Nature (London) 368:67-70 (1994).
Richard, S. et al., Inhibition of T-type calcium currents by dihydropyridines in mouse embryonic dorsal root ganglion neurons, Neuroscience Letters 132:229-234 (1991).
Rovnyak, G.C. et al., Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators, Journal of Medicinal Chemistry 38:199-129 (1995).
Soong, T. W. et al., Structure and functional expression of a member oflow voltage-activated calcium channel family, Science (Washington DC) 260:1133-1136 (1993).
Stea, A. et al., Voltage gated calcium channels, in Handbook of Receptors and Channels; Ligand and Voltage-Gated Ion Channels (North RA ed.) CRC Press Inc., Boca Raton, Florida 113-152 (1995).
Takahashi, K. et al., Kinetic properties of T-type- Ca2+currents in isolated rat hippocampal CAI pyramidal neurons, J. Neurophysiol. 65:148-155 (1991).
Tottene, A. et al., Functional diversity of P-type and R-type calcium channel in a rat cerebellar neurons, J. Neurosci. 16:6353-6363 (1996).
Tsien et al., Multiple types of neuronal calcium channels and their selective modulation, TINS 11:431-438 (1988).
Tsien, R. W. et al., Molecular diversity of voltage dependent Ca2+channels. Trends. Pharmacol. Sci. 12:349-354 (1991).
Wheeler, D. B. et al., Roles of N-type and Q type Ca2+channels in supporting hippocampal synaptic transmission, Science (Washington DC) 264:107-111 (1994).
Williams, M. E. et al., Structure and functional expression of alpha1, alpha2, and beta subunits of novel human neuronal calcium channel subtype, Neuron 8:71-84 (1992).
Zamponi, G. W., Antagonist binding sites of voltage-dependent calcium channels, Drug Development Research 42:131-143 (1997).
Alapati Srinivasa Rao
Bibbs Jeffrey A.
Pullela Phani Kumar
Rangappa Paramashivappa
Subbarao Pillarisetti V.
Davis Zinna N.
Knobbe Martens Olson and Bear LLP
Vittal Mallya Scientific Research
LandOfFree
1,4-dihydropyridine and pyridine compounds as calcium... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,4-dihydropyridine and pyridine compounds as calcium..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,4-dihydropyridine and pyridine compounds as calcium... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3858875